{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:01:42Z","timestamp":1745812902263,"version":"3.40.4"},"reference-count":16,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,8,13]]},"abstract":"<jats:p>A 13\u2005months old female baby born at 24\u2005weeks of gestational age (GA) presented with stage 4A retinopathy of prematurity (ROP) with plus disease in the right eye and stage 3 with plus disease in the left eye. The baby was diagnosed with stage 3 zone 2 ROP in both eyes with plus disease at 32\u2005weeks of GA and received intravitreal bevacizumab in both eyes. The baby received intravitreal bevacizumab and ranibizumab injections at 39 and 57\u2005weeks of postmenstrual age (PMA), respectively for recurrence. Laser treatment to peripheral avascular retina was carried out at 67\u2005weeks of PMA. The right eye progressed to stage 4A and left eye developed pre-retinal haemorrhages. This case reports late recurrence treated with initial multiple antivascular endothelial growth factor (VEGF) injections alone. One should be cautious in using anti-VEGF agents as a monotherapy in cases of ROP that appear different from the current understanding of the natural course of the disease.<\/jats:p>","DOI":"10.1136\/bcr-2016-216056","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T15:48:20Z","timestamp":1472485700000},"page":"bcr2016216056","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Smouldering retinopathy of prematurity: a case treated by multiple antivascular endothelial growth factor therapy"],"prefix":"10.1136","volume":"2016","author":[{"given":"Divya","family":"Balakrishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Ambiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhadra","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmaja Kumari","family":"Rani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,8,29]]},"reference":[{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.1","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-007-9066-0"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.12.023"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.050"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60178-6"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2015.01.009"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.8","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000380"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.9","first-page":"1162","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"368","author":"Hartnett","year":"2013","journal-title":"N Engl J Med"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.10","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-11625"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2014.03.011"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2011.11.021","article-title":"Bevacizumab for ROP","volume":"119","author":"Blair","year":"2012","journal-title":"Ophthalmology"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.13","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.3928\/01913913-20140930-01","article-title":"A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity","volume":"51","author":"Yaz","year":"2014","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.14","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-014-0502-0"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.10.007"},{"key":"2025042703563133000_2016.aug29_1.bcr2016216056.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.04.018"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-216056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:56:39Z","timestamp":1745751399000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-216056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,29]]},"references-count":16,"alternative-id":["10.1136\/bcr-2016-216056"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-216056","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2016,8,29]]}}}